FactSet Rates Corbus Pharmaceuticals Holdings as Buy with a Target Price

Summary

According to FactSet survey analysts, Corbus Pharmaceuticals Holdings, Inc. has an average rating of ‘buy,’ with an average price target of $45.11.Trading View

Impact Analysis

This event is classified at the company level, as it specifically pertains to Corbus Pharmaceuticals Holdings, Inc. The ‘buy’ rating and target price of $45.11 indicate positive analyst sentiment, suggesting potential upside in the stock price. Investors may view this as an opportunity to invest in Corbus Pharmaceuticals, particularly given the company’s focus on oncology and obesity, which are significant areas of innovation and growth. However, the recent report of a net loss of $17 million due to increased clinical development expenses Tip Ranks suggests financial challenges that investors should consider. The annual shareholder meeting conducted on May 15, 2025 Reuters, might have provided additional insights into the company’s strategies and future prospects. Opportunities exist for investors willing to weigh the analyst optimism against the company’s current financial situation.